Drug intelligence / Profile preview

THR-SK004

Development stage: Preclinical
Modality: Small Molecules
Administration: Topical

Overview

THR-SK004 is an ethanol extract derived from a traditional Thai herbal recipe, investigated for its therapeutic potential in wound treatment. It has demonstrated significant antibiofilm activity against bacterial pathogens such as *Pseudomonas aeruginosa* and *Staphylococcus epidermidis*, inhibiting biofilm formation and eradicating mature biofilms. Additionally, THR-SK004 exhibits antibacterial potency against methicillin-resistant *Staphylococcus aureus* (MRSA) and susceptible *S. aureus*, along with anti-inflammatory effects through the inhibition of lipopolysaccharide-induced nitric oxide production, and antioxidant activities via DPPH and hydroxyl radical scavenging. These multifaceted properties suggest its utility as a phytopharmaceutical for topical wound care.

Beyond the preview

Go deeper on THR-SK004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on THR-SK004.

Explore the full profile